ArticleJTCVS open2025
Applying expertise: Extrapleural pneumonectomy and extended pleurectomy decortication in the management of Masaoka-Koga stage IV thymoma.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advanced thymic epithelial tumours after neoadjuvant therapy: a narrative review of surgical challenges and strategies.Mediastinum (Hong Kong, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The European Society of Medical Oncology supports the use of surgery with adjuvant radiotherapy in resectable Masaoka-Koga Stage IV thymomas. We explore the role of extended pleurectomy decortication (EPD) and extrapleural pneumonectomy (EPP) in the management of patients with Masaoka-Koga stage IV thymic tumors with pleural involvement from our single-center experience. Methods: We conducted a retrospective analysis of patients who had undergone extended resections over a 10-year period for Masaoka-Koga stage IV thymomas at our thoracic unit in the United Kingdom. Data was gathered from patient records and electronic databases. Results: Ten patients were included in our series; 90% with primary thymoma and 10% with metastatic recurrence. In total, 80% of patients had EPD and 20% EPP; 60% had pericardium resected and 50% the ipsilateral hemidiaphragm. Length of stay was 2 to 21 days (median, 7 days). There was no in-hospital or 90-day mortality. Histology subtypes were variable: World Health Organization type AB (20%), B1 (10%), B2 (50%), and B3 (20%). A total of 60% of patients had R1 resection. All patients had adjuvant therapy. In total, 70% of patients had disease recurrence with an average disease-free interval of 44 months (range, 8 months to 10 years). Five-year survival was 90% with an overall survival of 60%. Conclusions: This series supports the use of extended resections in selected patients with Masaoka-Koga stage IV thymoma as part of multimodality treatment. EPP and EPD are not part of routine thoracic surgery practice in the United Kingdom. We suggest these cases are referred to dedicated centers with required expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.